Member of the Association of American Physicians
Ravindra Majeti mostly deals with Immunology, CD47, Stem cell, Haematopoiesis and Myeloid leukemia. The study of Immunology is intertwined with the study of Transplantation in a number of ways. His work in CD47 covers topics such as Cancer which are related to areas like Immune system.
The concepts of his Haematopoiesis study are interwoven with issues in Epigenetics and Cellular differentiation. His biological study spans a wide range of topics, including Myeloid, Leukemia and Mutation. His Phagocytosis research includes elements of Cancer research and Macrophage.
His primary areas of investigation include Cancer research, Haematopoiesis, Myeloid leukemia, Stem cell and Immunology. He has included themes like Cancer cell, Cancer, Immunotherapy, Antigen and Myelofibrosis in his Cancer research study. His Haematopoiesis research integrates issues from Progenitor cell, Molecular biology, Cellular differentiation and Bone marrow.
The study incorporates disciplines such as Enasidenib, Oncology, Mutation, Somatic evolution in cancer and Leukemia in addition to Myeloid leukemia. Ravindra Majeti usually deals with Leukemia and limits it to topics linked to Myeloid and Immunophenotyping. CD47, Antibody and B cell are among the areas of Immunology where the researcher is concentrating his efforts.
Ravindra Majeti focuses on Cancer research, Haematopoiesis, Myeloid leukemia, Cancer and Stem cell. The various areas that he examines in his Cancer research study include Cancer cell, Antigen, Leukemia, CD47 and Immunotherapy. His research links Myeloid with Leukemia.
His Haematopoiesis study incorporates themes from Progenitor cell, Cytokine, Computational biology and Bone marrow. His Myeloid leukemia study integrates concerns from other disciplines, such as Embryonic stem cell, Synthetic lethality, Transplantation and Oncology. His Stem cell study improves the overall literature in Cell biology.
His primary areas of study are Myeloid leukemia, Cancer research, Internal medicine, Oncology and Clinical significance. His work carried out in the field of Myeloid leukemia brings together such families of science as Enasidenib, IDH2, IDH1 and Synthetic lethality. His Cancer research research incorporates elements of Haematopoiesis, Erythropoiesis, Macrophage, Transplantation and Immunotherapy.
His study in Haematopoiesis focuses on Bone marrow failure in particular. His Immunotherapy research is multidisciplinary, incorporating perspectives in Myeloid, T cell, Acquired immune system and CD47. His Clinical significance study incorporates themes from Tumor microenvironment, Cancer, Cancer stem cell, Prognostic models and Clinical evaluation.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
CD47 is an adverse prognostic factor and therapeutic antibody target on human acute myeloid leukemia stem cells.
Ravindra Majeti;Mark P. Chao;Ash A. Alizadeh;Wendy W. Pang.
CD47 Is Upregulated on Circulating Hematopoietic Stem Cells and Leukemia Cells to Avoid Phagocytosis
Siddhartha Jaiswal;Catriona H.M. Jamieson;Wendy W. Pang;Christopher Y. Park.
The CD47-signal regulatory protein alpha (SIRPa) interaction is a therapeutic target for human solid tumors
Stephen B. Willingham;Jens Peter Volkmer;Andrew J. Gentles;Debashis Sahoo.
Proceedings of the National Academy of Sciences of the United States of America (2012)
Anti-CD47 Antibody Synergizes with Rituximab to Promote Phagocytosis and Eradicate Non-Hodgkin Lymphoma
Mark P. Chao;Ash A. Alizadeh;Chad Tang;June Helen Myklebust;June Helen Myklebust.
Lineage-specific and single-cell chromatin accessibility charts human hematopoiesis and leukemia evolution
M Ryan Corces;Jason D Buenrostro;Jason D Buenrostro;Beijing Wu;Peyton G Greenside.
Nature Genetics (2016)
CRISPR/Cas9 β-globin gene targeting in human haematopoietic stem cells
Daniel P. Dever;Rasmus O. Bak;Andreas Reinisch;Joab Camarena.
Clonal evolution of preleukemic hematopoietic stem cells precedes human acute myeloid leukemia.
Max Jan;Thomas M. Snyder;M. Ryan Corces-Zimmerman;Paresh Vyas.
Science Translational Medicine (2012)
Calreticulin Is the Dominant Pro-Phagocytic Signal on Multiple Human Cancers and Is Counterbalanced by CD47
Mark P. Chao;Siddhartha Jaiswal;Siddhartha Jaiswal;Rachel Weissman-Tsukamoto;Ash A. Alizadeh.
Science Translational Medicine (2010)
Preleukemic mutations in human acute myeloid leukemia affect epigenetic regulators and persist in remission
M. Ryan Corces-Zimmerman;Wan-Jen Hong;Irving L. Weissman;Bruno C. Medeiros.
Proceedings of the National Academy of Sciences of the United States of America (2014)
CD47 Blockade by Hu5F9-G4 and Rituximab in Non-Hodgkin's Lymphoma.
Ranjana Advani;Ian Flinn;Leslie Popplewell;Andres Forero.
The New England Journal of Medicine (2018)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: